Dicks Sporting Goods Inc vs Cassava Sciences Inc — how do they compare? Dicks Sporting Goods Inc trades at $211.39 (market cap $18.92B), while Cassava Sciences Inc trades at $1.09 (market cap $52.66M). The key difference: Dicks Sporting Goods Inc is far larger — about 359.3× Cassava Sciences Inc's market cap, and Dicks Sporting Goods Inc pays a 2.37% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| DKS | FLNA | |
|---|---|---|
Market Cap | $18.92B | $52.66M |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $4.64 |
52-Week Low | $187.78 | $1.09 |
Enterprise Value | $25.71B | -$33.92M |
Dividend Yield | 2.37% | — |
Signals from Pluang's Aura AI — not financial advice
Dick's Sporting Goods (DKS) trades at $216.10, down 0.86% with a bearish technical outlook despite strong fundamentals. The company reported consistent earnings beats, with Q1 2026 EPS of $2.90 exceeding expectations, and maintains solid profitability with a 4.71% net margin. Recent developments include the launch of ScoreCard+ loyalty program and Lids partnership expansion. Analyst consensus remains strongly bullish with a $261 price target, though legal scrutiny over fiduciary duties presents near-term headwinds.
DKS offers attractive valuation with a P/E of 20.58 and P/S of 0.96, trading below analyst targets. Growth catalysts include market share gains and strategic partnerships, but risks involve competitive pressures and potential legal overhangs. The stock's current dip may present a buying opportunity for long-term investors given fundamental strength and institutional support.
FLNA trades at $1.15, down 2.54% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company continues to report losses, with a net income of -$90.97M in 2025 and negative cash flow, though it has beaten EPS estimates for the last three quarters. Recent news highlights ongoing development in its TSC-related epilepsy therapies.
Despite consistent earnings beats, FLNA's negative profitability and cash burn pose significant risks. Analyst sentiment is positive with a 66.7% buy rating, but the stock's outlook depends heavily on clinical success and future funding. Investors should weigh the high-risk, high-reward nature of this biotech play.
Trailing returns across standard periods
Latest headlines on both assets
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →